Clinical Trial Update: Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE [Phase 3]

View source ↗

Summary

Phase 3 trial comparing non-immunogenic recombinant staphylokinase with alteplase for massive pulmonary embolism has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Massive Pulmonary Embolism

Drugs mentioned

• Alteplase (alteplase)
• Non-immunogenic recombinant staphylokinase (staphylokinase)

Snippet

Sponsor: Supergene, LLC | Conditions: Massive Pulmonary Embolism | Phase 3 | Status: COMPLETED | Results posted: 2025-04-02